iRhythm Technologies, Inc. (IRTC) Analysts See $-0.42 EPS

July 27, 2018 - By Billy Entrekin

Analysts expect iRhythm Technologies, Inc. (NASDAQ:IRTC) to report $-0.42 EPS on August, 1 after the close.They anticipate $0.13 EPS change or 44.83 % from last quarter’s $-0.29 EPS. After having $-0.47 EPS previously, iRhythm Technologies, Inc.’s analysts see -10.64 % EPS growth. The stock decreased 5.44% or $4.43 during the last trading session, reaching $76.95. About 397,372 shares traded or 35.04% up from the average. iRhythm Technologies, Inc. (NASDAQ:IRTC) has risen 103.18% since July 27, 2017 and is uptrending. It has outperformed by 90.61% the S&P500.

iRhythm Technologies, Inc., a digital healthcare company, focuses on the provision of ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias in the United States. The company has market cap of $1.82 billion. It offers ZIO Service, a platform that provides wearable biosensor with cloud data analytics that distill data from heartbeats into clinically actionable information. It currently has negative earnings.

More notable recent iRhythm Technologies, Inc. (NASDAQ:IRTC) news were published by: which released: “iRhythm Technologies (IRTC) Announces Karim Karti as COO” on June 28, 2018, also with their article: “Premarket analyst action – healthcare” published on July 16, 2018, published: “iRhythm Technologies: Looming Reimbursement Cut And Highly Motivated Competition Should Give Investors …” on July 26, 2018. More interesting news about iRhythm Technologies, Inc. (NASDAQ:IRTC) were released by: and their article: “5 MedTech Stocks That Perfectly Blend Healthcare and Technology” published on July 20, 2018 as well as‘s news article titled: “Study Results Show Zio by iRhythm Improves Detection of Asymptomatic Atrial Fibrillation in At-Risk Population” with publication date: July 10, 2018.

iRhythm Technologies, Inc. (NASDAQ:IRTC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.